CLASS II Drug recall · Reported 20 Nov 2019 · FDA Enforcement Report

Equate Maximum Strength Ranitidine Tablets, USP 150 mg Acid Reducer recalled

Apotex is recalling Equate Maximum Strength Ranitidine Tablets, USP 150 mg Acid Reducer, distributed nationwide in the US. The recall was initiated on 24 Sep 2019 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesAll lots remaining within expiry.
Quantity recalled1,132,453 bottles

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

Recall details

Recall number
D-0316-2020
FDA event ID
83871
Recalling firm
Apotex, North York, N/A
Classification
Class II
Status
Completed
Recall initiated
24 Sep 2019
FDA classified
12 Nov 2019
Reported
20 Nov 2019
Type
Voluntary: Firm initiated
Customers notified by
Press Release
Reason category
Nitrosamine Impurity

Timeline

24 Sep 2019Recall initiated by company
12 Nov 2019Classified by FDA+49 days
20 Nov 2019Published in enforcement report+8 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

GGMP Deviations: Possible contamination with impurity N-nitrosodimethylamine (NDMA).

Nitrosamines are impurities that can form during drug manufacturing or storage. Above the FDA acceptable intake limit, long-term exposure may raise cancer risk. The FDA advises patients to keep taking the medicine until they have a replacement.

Product as listed by the FDA

Equate Maximum Strength Ranitidine Tablets, USP 150 mg Acid Reducer 130 Tablets Distributed by Wal-Mart Stores, Inc. Bentonville, AR 72716 a) Twin Pack NDC: 49035-100-07; b) Single Pack NDC: 49035-100-00

Where it was distributed

Nationwide

Nationwide

Stores named: Walmart

Questions about this recall

Is Equate Maximum Strength Ranitidine Tablets, USP 150 mg Acid Reducer recalled?

Yes. Apotex recalled Equate Maximum Strength Ranitidine Tablets, USP 150 mg Acid Reducer on 24 Sep 2019. The recall is Class II and its status is Completed. Recall number D-0316-2020.

Why was it recalled?

GGMP Deviations: Possible contamination with impurity N-nitrosodimethylamine (NDMA).

Which lots are affected?

All lots remaining within expiry.

Where was it sold?

Nationwide

What should I do if I have it?

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 21 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from Apotex

All 75
ReportedClassRecallCompanyReasonWhere
DrugCLASS IIPaxil CR, Paroxetine, Extended-Release Tablets, 5mg recalled by ApotexPaxilApotexPotency & AssayNationwide
DrugCLASS IIDesmopressin Nasal Spray, USP, 10 mcg/ bottle (50 doses) recalledApotexOtherNationwide
DrugCLASS IIBrimonidine Tartrate/Timolol Maleate Ophthalmic Solution 2%/0.5%* recalledBrimonidine Tartrate/timolol Maleate Ophthalmic SolutionApotexSterilityNationwide
DrugCLASS IIKetorolac Tromethamine Ophthalmic Solution recalled by ApotexKetorolac TromethamineApotexSterilityNationwide
DrugCLASS IIBrimonidine Tartrate/Timolol Maleate Ophthalmic Solution recalledBrimonidine Tartrate/timolol Maleate Ophthalmic SolutionApotexSterilityNationwide

Other Equate maximum strength ranitidine recalls

All 2
ReportedClassRecallCompanyReasonWhere
DrugCLASS IIEquate Maximum Strength Ranitidine Tablets recalled by ApotexApotexNitrosamine ImpurityNationwide